A promising molecule, an impressive artificial intelligence model, a quantum processor that crushes a benchmark: the press release arrives, bringing a “revolution” with it. Yet just a few words can open a gulf between what was observed and what the public understands. Looking ahead to September 2026, the challenge for science communicators will be less about speaking louder than about making the road still ahead visible. This analysis draws on documented events; its projections into 2026 are forward-looking assessments, not established facts.
Four stages, four different promises
The first task begins before the headline: identifying the nature of the announcement. A preprint makes research accessible before any potential peer review. It accelerates the circulation of knowledge, but its methods and conclusions may still change. A peer-reviewed publication adds another filter, not a certificate of infallibility. Errors may remain; a single study does not necessarily establish a consensus.
A demonstration answers a different question: can something be made to work under selected conditions? Deployment asks whether it works reliably over time, with real users, economic constraints, risks and incidents. These categories do not necessarily form a mandatory sequence: a product can be marketed without a scientific publication, while a rigorously published result may remain unusable in practice.
To avoid confusion, every announcement should make four elements easy to identify:
- The result: what was actually measured or observed.
- The setting: the data, participants, equipment and test conditions.
- The validation: scientific review, independent replication or relevant regulatory scrutiny.
- The availability: a prototype, a limited trial, an accessible service or routine use.
AI: a score does not tell the story of real-world work
In AI, the classic shortcut is to turn performance on a benchmark into general competence. A model solves a series of problems; suddenly, it is presented as capable of replacing an entire profession. Yet a test measures a defined task under a specific protocol. It tells us less directly about reliability when dealing with ambiguous requests, incomplete documents or errors that cannot be detected without expertise.
AlphaFold offers a more instructive example than the divide between enthusiasm and skepticism. Advances in protein structure prediction, particularly with AlphaFold 2, have greatly enriched the tools available to researchers. But predicting a structure is not the same as demonstrating a drug’s efficacy. Biological interactions still need to be understood, hypotheses tested, and a candidate’s safety and then clinical benefit established.
The publication of AlphaFold 3 in Nature in May 2024 expanded the ambition to predicting interactions between several types of molecules. Discussions about access to the model and opportunities for replication also served as a reminder that an announcement has two dimensions: what the team claims to have achieved and what others can actually verify. Transparency about access conditions is part of the scientific story.
Show the cases that remain challenging, too
For a company launching an assistant, a convincing demonstration should therefore come with a defined scope: which tasks, what supervision, what known limitations? Showing a representative failure may seem counterintuitive. Yet it provides useful information for the buyer. A successful sequence demonstrates a possibility; it documents neither the frequency of errors nor their severity.
Healthcare: do not confuse hope with established benefit
In healthcare, overpromising affects people who may be waiting for a treatment option. A decline in a biological marker does not automatically mean an improvement in survival or quality of life. A result in mice does not describe a treatment available to humans. And an early-stage trial, often focused on safety, does not support the same conclusions as a robust comparative clinical study.
The first approvals of Casgevy in late 2023 marked a genuine milestone for CRISPR-based gene editing. The United Kingdom approved it for certain forms of sickle cell disease and beta-thalassemia; the United States initially approved it for sickle cell disease. Calling this a breakthrough is defensible. But it still requires explaining that this is a specialized medical process involving the collection and modification of a patient’s cells, followed by an intensive conditioning regimen before those cells are reinfused.
Telling only the story of “genetic scissors” leaves out the hospital, eligibility criteria, side effects and barriers to access. Regulatory approval means neither universal availability nor an absence of long-term uncertainty. A sound account connects the biological innovation with the practical conditions of care. It does not diminish the advance: it puts its significance into proper perspective.
Quantum computing: an experimental victory is not a market
Quantum computing presents another difficulty: some experiments are remarkable precisely because they explore highly specific tasks. In 2019, Google published a result using its Sycamore processor that was presented as a milestone in “quantum supremacy.” The work involved random circuit sampling, not the immediate optimization of a supply chain or the discovery of a drug.
Debates over comparisons with classical computers showed just how much the choice of problem, resources and reference methods matters. Saying “faster” without saying “at what” creates a misleading understanding. Credible communication therefore distinguishes experimental progress, error correction, scaling up and useful advantage for an application. These stages are connected, but none automatically guarantees the next.
Build in precision before the press conference
The solution is not a discreet caveat in a footnote. It requires having the announcement reviewed by researchers, but also by someone able to identify what a nonspecialist reader will infer from it. Does the headline promise more than the data support? Does the illustration show a product that does not exist? Is the future presented as a roadmap or as an established result?
A useful press kit includes a link to the original research, its status, relevant funding, the main limitations and the next validation step. It also distinguishes the team’s results from outside assessments. For spokespeople, preparing a clear answer to “what does this not prove?” is better than crafting a spectacular line that will be impossible to defend after publication.
What now? Between now and September 2026 and beyond, the proliferation of announcements can be expected to make this discipline more valuable. Organizations that document their uncertainties could gain credibility with journalists, partners and the public. Nothing guarantees that they will dominate every news cycle. But describing a breakthrough accurately will give them a lasting advantage: the ability to announce the next step without having to rewrite the previous one.